Hospital
Appalachian Regional Healthcare, INC
Appalachian Regional Healthcare, INC was paid $18.33M by Medicaid between Jan 2018 and Dec 2024, across 256 billing codes. Its largest line is 99284, emergency room visit (serious) — 9.6% of everything it billed.
33Billing provider infoAPPALACHIAN REGIONAL HEALTHCARE, INC
BECKLEY, WV 25801
BECKLEY, WV 25801
33aNPI1568461440assigned 07/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.33M
24GClaims554,047
24DCodes billed256
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#14 of 26
Median peer was paid$18.33M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 139,235 | $5.96M | |
| 2019 | 86,049 | $2.74M | |
| 2020 | 111,391 | $4.08M | |
| 2021 | 83,259 | $1.82M | |
| 2022 | 48,571 | $1.26M | |
| 2023 | 45,906 | $1.34M | |
| 2024incomplete | 39,636 | $1.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.6% | 15,777 | 13,315 | $1.77M |
| 41899 | Unlisted procedure, dentoalveolar structures | 8.8% | 1,566 | 1,318 | $1.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 5,289 | 4,388 | $1.29M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.2% | 15,321 | 13,553 | $1.14M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.4% | 52,706 | 39,093 | $628K |
| 80053 | Comprehensive metabolic panel | 3.2% | 41,905 | 33,084 | $595K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.9% | 11,572 | 9,697 | $525K |
| G0378 | Hospital observation service, per hour | 2.4% | 1,042 | 651 | $448K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.4% | 7,110 | 5,755 | $444K |
| 36415 | Collection of venous blood by venipuncture | 2.4% | 34,794 | 24,549 | $444K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.3% | 1,220 | 1,099 | $417K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 3,181 | 2,733 | $355K |
244 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 7,855 | $333K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 4,103 | $278K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 6,605 | $263K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 3,506 | $222K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 12,240 | $217K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 15,153 | $207K |
| 81001 | 1.1% | 17,500 | $202K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 5,523 | $199K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.1% | 1,008 | $195K |
| 84484 | <1% | 10,658 | $169K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 417 | $168K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,053 | $165K |
| 80061 | Lipid panel | <1% | 9,251 | $146K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,014 | $144K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,917 | $144K |
| 83735 | <1% | 12,027 | $136K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,834 | $132K |
| 87040 | <1% | 5,502 | $127K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 17,896 | $124K |
| 82150 | <1% | 3,688 | $124K | |
| 83690 | <1% | 6,462 | $113K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,222 | $109K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,897 | $108K |
| 85730 | <1% | 5,588 | $108K | |
| 82553 | <1% | 5,940 | $108K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,308 | $103K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,608 | $100K |
| 85610 | <1% | 7,687 | $99K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,747 | $98K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 985 | $95K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,311 | $94K |
| 83605 | <1% | 4,614 | $94K | |
| 82550 | <1% | 6,397 | $91K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,096 | $88K |
| 84703 | <1% | 2,058 | $88K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 172 | $83K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 876 | $80K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 547 | $77K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,701 | $76K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 539 | $74K |
| 74178 | <1% | 282 | $70K | |
| 83880 | <1% | 3,195 | $69K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,212 | $68K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 409 | $68K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,612 | $68K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,050 | $68K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,887 | $66K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,241 | $65K |
| 88312 | <1% | 1,007 | $63K | |
| 73560 | <1% | 3,129 | $63K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 357 | $63K |
| 96367 | <1% | 1,389 | $62K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,524 | $60K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,130 | $59K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 630 | $58K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,129 | $58K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 864 | $56K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,728 | $55K |
| 96376 | <1% | 1,279 | $52K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 645 | $51K |
| 73030 | <1% | 1,550 | $50K | |
| 84145 | <1% | 2,442 | $48K | |
| 80076 | <1% | 3,471 | $47K | |
| 86140 | <1% | 3,005 | $45K | |
| 80299 | <1% | 285 | $45K | |
| 93017 | <1% | 556 | $44K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,453 | $44K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 501 | $43K |
| 81025 | <1% | 4,297 | $41K | |
| 72131 | <1% | 372 | $41K | |
| 85652 | <1% | 3,142 | $41K | |
| 82607 | <1% | 3,235 | $38K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 572 | $34K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,960 | $34K |
| 87522 | Neg quan hep c or qual rna | <1% | 844 | $34K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,318 | $33K |
| 87186 | <1% | 1,832 | $31K | |
| 84439 | <1% | 2,519 | $29K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 243 | $29K |
| 93971 | <1% | 467 | $29K | |
| 80074 | <1% | 851 | $28K | |
| 87070 | <1% | 860 | $27K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,007 | $27K |
| 93041 | <1% | 3,129 | $26K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 847 | $26K |
| 72100 | <1% | 945 | $26K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 385 | $24K |
| A9270 | Non-covered item or service | <1% | 2,468 | $24K |
| 78454 | <1% | 104 | $23K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,746 | $23K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 308 | $22K |
| 82803 | <1% | 750 | $20K | |
| J3490 | Unclassified drugs | <1% | 1,028 | $19K |
| 73610 | <1% | 590 | $18K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 901 | $18K |
| 80069 | <1% | 1,276 | $18K | |
| 84100 | <1% | 1,257 | $18K | |
| 73630 | <1% | 574 | $18K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 368 | $17K |
| 93458 | <1% | 75 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 746 | $17K |
| 73130 | <1% | 444 | $17K | |
| 87077 | <1% | 851 | $17K | |
| 36591 | <1% | 138 | $16K | |
| 73110 | <1% | 467 | $16K | |
| 74018 | <1% | 793 | $16K | |
| 71250 | <1% | 269 | $15K | |
| 88304 | <1% | 312 | $15K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 20 | $13K |
| 80164 | <1% | 990 | $13K | |
| 82565 | <1% | 1,212 | $13K | |
| 82728 | <1% | 1,047 | $13K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 475 | $12K |
| 73562 | <1% | 658 | $12K | |
| 97014 | <1% | 317 | $12K | |
| 36600 | <1% | 668 | $12K | |
| 97035 | <1% | 322 | $12K | |
| 81002 | <1% | 655 | $12K | |
| 84520 | <1% | 1,138 | $11K | |
| 83540 | <1% | 1,250 | $11K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,243 | $11K |
| 85378 | <1% | 885 | $11K | |
| 86592 | <1% | 519 | $11K | |
| 87076 | <1% | 1,087 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 396 | $10K |
| 99218 | <1% | 382 | $10K | |
| 82746 | <1% | 894 | $10K | |
| 80050 | General health panel | <1% | 412 | $10K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 183 | $9K |
| 84702 | <1% | 296 | $9K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 232 | $9K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 183 | $8K |
| 0100U | <1% | 179 | $8K | |
| 96368 | <1% | 82 | $8K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 110 | $8K |
| 82140 | <1% | 665 | $7K | |
| 84436 | <1% | 304 | $7K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 252 | $7K |
| 83883 | <1% | 117 | $7K | |
| 86706 | <1% | 215 | $7K | |
| 86708 | <1% | 184 | $6K | |
| 97162 | <1% | 174 | $6K | |
| 73502 | <1% | 287 | $6K | |
| 83550 | <1% | 748 | $6K | |
| 86704 | <1% | 181 | $6K | |
| 87340 | <1% | 184 | $6K | |
| 87631 | <1% | 113 | $6K | |
| 85379 | <1% | 299 | $6K | |
| 83010 | <1% | 158 | $5K | |
| 72040 | <1% | 155 | $4K | |
| 94060 | <1% | 287 | $4K | |
| C1769 | Guide wire | <1% | 405 | $4K |
| 87902 | <1% | 40 | $4K | |
| 80202 | <1% | 340 | $4K | |
| 73522 | <1% | 86 | $3K | |
| 86901 | <1% | 125 | $3K | |
| 86900 | <1% | 125 | $3K | |
| 94729 | <1% | 174 | $3K | |
| 94726 | <1% | 189 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,630 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 64 | $3K |
| 82977 | <1% | 71 | $3K | |
| 76000 | <1% | 91 | $3K | |
| 84153 | <1% | 148 | $3K | |
| 82248 | <1% | 104 | $3K | |
| 74022 | <1% | 89 | $3K | |
| 86707 | <1% | 67 | $2K | |
| 87350 | <1% | 67 | $2K | |
| 84460 | <1% | 66 | $2K | |
| 84550 | <1% | 290 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 68 | $2K |
| 87536 | <1% | 68 | $2K | |
| 82652 | <1% | 68 | $2K | |
| 93970 | <1% | 27 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $2K |
| 82247 | <1% | 51 | $2K | |
| 82172 | <1% | 36 | $2K | |
| 80178 | <1% | 153 | $2K | |
| 86709 | <1% | 65 | $2K | |
| 82009 | <1% | 33 | $2K | |
| 87634 | <1% | 30 | $1K | |
| 92523 | <1% | 15 | $1K | |
| 80143 | <1% | 96 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 32 | $1K |
| 73080 | <1% | 42 | $1K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 30 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 97 | $1K |
| 82043 | <1% | 285 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 49 | $1K |
| 84480 | <1% | 66 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 26 | $1K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $961.27 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 98 | $927.12 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $881.19 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $881.19 |
| 83615 | <1% | 119 | $800.39 | |
| 76536 | <1% | 12 | $794.29 | |
| 97161 | <1% | 18 | $711.41 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 34 | $669.04 |
| 86850 | <1% | 80 | $668.80 | |
| 84146 | <1% | 29 | $655.28 | |
| 84479 | <1% | 55 | $622.01 | |
| 97166 | <1% | 12 | $591.78 | |
| 86360 | <1% | 19 | $575.09 | |
| 86359 | <1% | 19 | $575.01 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 66 | $503.93 |
| 94760 | <1% | 114 | $466.08 | |
| 73590 | <1% | 17 | $457.46 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 15 | $454.71 |
| 85027 | <1% | 94 | $433.77 | |
| 86703 | <1% | 47 | $413.55 | |
| 90662 | <1% | 12 | $391.75 | |
| 88142 | <1% | 13 | $374.36 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 15 | $344.85 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 50 | $323.79 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 22 | $281.67 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 26 | $274.24 |
| 81003 | <1% | 71 | $226.18 | |
| 82533 | <1% | 20 | $203.19 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 201 | $193.45 |
| 83921 | <1% | 13 | $191.85 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 77 | $181.25 |
| 83090 | <1% | 14 | $179.03 | |
| 80183 | <1% | 17 | $169.00 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 44 | $162.93 |
| 51702 | <1% | 13 | $143.30 | |
| 82570 | <1% | 40 | $124.99 | |
| 93246 | <1% | 16 | $123.98 | |
| 85045 | <1% | 16 | $123.28 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 14 | $106.88 |
| 81015 | <1% | 62 | $105.32 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 65 | $92.90 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 48 | $87.87 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 100 | $81.93 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 19 | $63.94 |
| 87449 | <1% | 22 | $58.50 | |
| 84156 | <1% | 14 | $44.39 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 51 | $34.99 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 17 | $21.84 |
| 80047 | <1% | 13 | $16.28 | |
| 90686 | <1% | 66 | $10.35 | |
| 83704 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 36 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.